Johnson & Johnson $JNJ Stock Holdings Decreased by Horizon Kinetics Asset Management LLC

Horizon Kinetics Asset Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,302 shares of the company’s stock after selling 310 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in Johnson & Johnson were worth $2,948,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth $35,000. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth about $48,000. Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson during the 1st quarter valued at about $52,000. Finally, Pandora Wealth Inc. acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at about $65,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on JNJ. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Citigroup raised their price target on Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Raymond James Financial boosted their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Finally, Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $201.05.

Johnson & Johnson Stock Up 0.4%

JNJ opened at $203.88 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $206.94. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The business has a 50 day moving average price of $188.25 and a 200 day moving average price of $171.78. The firm has a market cap of $491.21 billion, a P/E ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.